Summit Therapeutics Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Summit Therapeutics Inc. (SMMT) holds an ST Score of 41.9 out of 100 (C), with its strongest factor being Momentum (A) and its weakest Growth (F). Analysts rate SMMT Buy across 23 ratings with a $26.86 average price target (+0.6% vs the current $16.90).
- Strongest
- MomentumA
- Weakest
- GrowthF
All factor grades
- MomentumA
- ForecastA-
- ValuationB-
- Financial StrengthC+
- ProfitabilityF
- GrowthF
- Piotroski2/9
Contact
SMMT stock: frequently asked questions
What is SMMT's ST Score?
Summit Therapeutics Inc. (SMMT) has an ST Score of 41.9 out of 100, an overall grade of C. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is SMMT a buy, sell, or hold?
Wall Street's consensus rating on SMMT is Buy based on 23 analyst ratings. Our own ST Score grades it C (41.9/100). This is data, not investment advice — always do your own research.
What is SMMT's valuation grade?
Summit Therapeutics Inc. (SMMT) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is SMMT's growth grade?
Summit Therapeutics Inc. (SMMT) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is SMMT's profitability grade?
Summit Therapeutics Inc. (SMMT) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is SMMT's financial strength grade?
Summit Therapeutics Inc. (SMMT) earns a financial strength grade of C+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for SMMT?
The average analyst price target for Summit Therapeutics Inc. (SMMT) is $26.86 from 23 analysts, which is +0.6% versus the recent price of $16.90.
What is SMMT's Piotroski score?
Summit Therapeutics Inc. (SMMT) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.